文献速递系统性红斑狼疮

阿尼鲁单抗快速降低狼疮肾炎肾内炎症尿液生物标志物:2期随机试验结果

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.
PubMed 文献 · Arthritis Rheumatol · 2026-03-16

该研究基于TULIP-LN 2期试验,对接受标准治疗的狼疮肾炎患者尿液进行蛋白质组学分析,比较阿尼鲁单抗基础方案、强化方案与安慰剂对197种蛋白的影响。结果显示阿尼鲁单抗在第12周显著降低尿CD163和MCP-1,且第48周各组生物标志物均下降但标准治疗起效更慢。

要点

  • 阿尼鲁单抗较安慰剂在第12周显著降低狼疮肾炎患者尿CD163和MCP-1。
  • 蛋白尿未应答者中仍可见上述生物标志物下降。
  • 第48周各组生物标志物均下降,提示标准治疗亦可抑制肾内炎症但更慢。

核心结论

  • 与安慰剂相比,阿尼鲁单抗显著降低狼疮肾炎患者反映肾脏组织学活动的尿液生物标志物,可能加速肾内炎症消退。

研究设计与样本

  • 基于TULIP-LN 2期随机试验(NCT02547922),收集第0、12、48周尿液,比较阿尼鲁单抗基础方案(n=35)、强化方案(n=42)与安慰剂(n=35)联合标准治疗对197种蛋白的影响。

主要发现

  • 第12周阿尼鲁单抗较安慰剂显著降低尿CD163和单核细胞趋化蛋白1(MCP-1)表达,包括所有方案中分类为蛋白尿未应答者的患者。
  • 第48周所有组生物标志物水平均下降,提示标准治疗单独也可最终抑制肾内炎症但动力学更慢。
  • 蛋白质组学分析显示阿尼鲁单抗在降低蛋白质组炎症特征方面优于安慰剂,无论应答状态如何。

临床怎么用

  • 尿CD163和MCP-1或可作为狼疮肾炎肾内炎症活动的早期监测标志物,阿尼鲁单抗可能加速炎症消退。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP-LN, ClinicalTrials.gov identifier NCT02547922). We studied the impact of anifrolumab treatment on urinary biomarker expression in patients with LN through proteomic analysis of samples from TULIP-LN. METHODS: Urine samples were collected at weeks 0, 12, and 48 from patients treated with the anifrolumab basic regimen (n = 35), intensified regimen (n = 42), or placebo (n = 35), in addition to standard therapy, and analyzed for the presence of 197 proteins. The impact of anifrolumab relative to placebo on prespecified biomarkers linked to histologic activity was assessed, and a comparison of responders versus nonresponders was conducted on proteins detected in ≥75% of samples. RESULTS: Anifrolumab treatment significantly reduced urinary CD163 and monocyte chemoattractant protein 1 expression at week 12 versus placebo, including in patients classified as proteinuric nonresponders across all regimens. By week 48, biomarker levels declined in all groups, indicating that standard therapy alone can eventually suppress intrarenal inflammation but with slower kinetics. Proteomic analyses further revealed that anifrolumab was superior to placebo in reducing the proteomic inflammatory signature, regardless of responder status. CONCLUSION: Compared with placebo, anifrolumab treatment significantly reduced urinary biomarkers of renal histologic activity in patients with LN, which may accelerate the resolution of intrarenal inflammation, potentially preventing damage accrual.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fava A, Petri M, Gavin PG, et al. Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial. Arthritis Rheumatol. 2026. PMID: 41663906. doi:10.1002/art.70089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。